Skip to Main Content

Author Details

Michael F Press
1977
245
80
PMIDPaper TitleJournal TitlePublished Year
36921335Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.J Clin Oncol2023
37402878Immunoassay-based quantification of full-length peptidylglycine alpha-amidating monooxygenase in human plasma.2023
37339271Discordance of HER2 Expression and/or Amplification on Repeat Testing.Mol Cancer Ther2023
37269905ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.Ann Oncol2023
36884217Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.Clin Cancer Res2023
36631725Tumor biomarkers and efficacy in patients treated with trastuzumab emtansineâ¿¿+â¿¿pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).Breast Cancer Res2023
35000083Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer.Annals of Surgical Oncology2022
36358657A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix<sup>®</sup> PC1 System.Cancers (Basel)2022
35384873A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine TherapApplied Immunohistochemistry and Molecular Morphology2022
35681773Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer.Cancers2022
35554533Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach.Hum Mol Genet2022
35925453Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study.Breast Cancer Res Treat2022
35291014A Systematic Review and Meta-Analysis of Smoking and Circulating Sex Hormone Levels Among Premenopausal Women.Nicotine Tob Res2022
35258770Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer.Annals of Surgical Oncology2022
34966897Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.Nat Cancer2021
34234117Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women.Nat Commun2021
33951110Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.PLoS One2021
33769540Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.J Natl Cancer Inst2021
33713608Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry.Am J Hum Genet2021
32822287Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic BreastJournal of Clinical Oncology2021
34625570A careful reassessment of anthracycline use in curable breast cancer.NPJ Breast Cancer2021
32852708Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.Breast Cancer Res Treat2020
31601552Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers.Cancer Discov2020
32139271A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.Clinical Breast Cancer2020
32014370Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).Clin Breast Cancer2020
31935283A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.Blood Adv2020
31615937Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer.Clin Cancer Res2020
33203854Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).Nat Commun2020
33199723Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&amp;E stains.Nat Commun2020
32697890Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.Cancer Medicine2020
31097597Role for polo-like kinase 4 in mediation of cytokinesis.Proc Natl Acad Sci U S A2019
30520947Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.JAMA Oncol2019
30737380Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.Nat Commun2019
31147552Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.Nat Commun2019
29846104Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.Arch Pathol Lab Med2018
30120700Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.Breast Cancer Research and Treatment2018
30485824Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.Cell Rep2018
29868978RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.Annals of Surgical Oncology2018
30572639CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.Cancers2018
30089602Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.Lung Cancer2018
29357906Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.Breast Cancer Res2018
29244528Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic BreastJournal of Clinical Oncology2018
29846122Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.J Clin Oncol2018
28123601Human-derived normal mesenchymal stem/stromal cells in anticancer therapies.Journal of Cancer2017
28430825Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium.PLoS Genet2017
28377418Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry.Cancer Epidemiol Biomarkers Prev2017
28649645A functionally significant SNP in TP53 and breast cancer risk in African-American women.NPJ Breast Cancer2017
27811012HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.Mol Cancer Ther2017
28086982Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.Breast Cancer Res2017
27587788A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.Cancer Epidemiol Biomarkers Prev2016
  • 1 - 50 of 245

Recommended Authors

Collaborators

Co-authored papers 69
David Geffen School of Medicine at university of california los angeles
Co-authored papers 44
University of Southern California
Co-authored papers 34
Co-authored papers 31
Co-authored papers 29
Roswell Park Comprehensive Cancer Center
Co-authored papers 28
Co-authored papers 26
Co-authored papers 26
University of Southern California
Co-authored papers 25
Co-authored papers 25
Co-authored papers 25
National Cancer Institute, National Institutes of Health
Co-authored papers 24
Co-authored papers 22
Co-authored papers 22
Co-authored papers 21
Co-authored papers 20
Vanderbilt University Medical Center
Co-authored papers 19
Keck School of Medicine, University of Southern California
Co-authored papers 16
Co-authored papers 16
Center for Pharmacoepidemiology and Treatment Science, Rutgers University
Co-authored papers 16
Co-authored papers 12
Co-authored papers 12
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 11
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 10
Co-authored papers 10
Stanford University School of Medicine
Co-authored papers 10
Co-authored papers 10
Co-authored papers 10
Morehouse School of Medicine
Co-authored papers 10
Co-authored papers 9